Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Relay Therapeutics is a clinical-stage precision medicine company developing allosteric inhibitors targeting oncology and genetic diseases using its proprietary Dynamo platform, which combines computational biophysics with structural biology to map protein motion. The company's lead programs include lirafugratinib (RLY-4008) for FGFR2-altered solid tumors and RLY-2608 for PI3Kα-mutant cancers, both in Phase 2 trials as of early 2026. Stock performance is driven by clinical trial readouts, regulatory milestones, and partnership announcements rather than revenue generation.
Relay operates a classic biotech model: burn cash through R&D to advance drug candidates through clinical trials, monetize through strategic partnerships (upfront payments, milestones, royalties), and ultimately commercialize approved therapies. The Dynamo platform provides differentiation by identifying allosteric binding sites that competitors miss with traditional structure-based design. Partnership economics typically involve $50-200M upfronts, $500M-1B+ in milestone potential, and mid-single to low-double digit royalties. Current burn rate approximately $200M annually suggests 3-4 years of runway based on ~$600M cash position (estimated Q4 2025).
Clinical trial data readouts for lirafugratinib (RLY-4008) in FGFR2+ cholangiocarcinoma and other solid tumors - objective response rates above 30% would be viewed positively
FDA regulatory interactions including Breakthrough Therapy Designation applications, IND clearances for new programs, and potential accelerated approval pathways
Strategic partnership announcements with big pharma for pipeline programs, particularly upfront payments exceeding $100M
Competitive developments in FGFR2 and PI3Kα inhibitor space, including approvals or failures of rival programs from Incyte, Novartis, or Taiho
Cash runway updates and financing activities - equity raises dilute but extend operational timeline
Clinical trial failure risk - oncology programs historically have ~10-15% Phase 2 to approval success rates; single negative readout can eliminate 50%+ of market cap
Regulatory pathway uncertainty for novel allosteric mechanisms - FDA may require larger datasets or longer follow-up than anticipated for accelerated approvals
Platform technology risk - if Dynamo-discovered compounds fail to show differentiation versus traditional inhibitors, core thesis is undermined
Reimbursement pressure on specialty oncology drugs - payers increasingly scrutinizing $150K+ annual treatment costs even for targeted therapies
FGFR2 inhibitor competition from Incyte's pemigatinib (approved), Taiho's futibatinib (approved), and Novartis programs - market may fragment with multiple entrants
PI3Kα space crowded with Novartis (alpelisib approved), Eli Lilly, and multiple clinical-stage competitors - differentiation on safety/efficacy profile critical
Large pharma in-house computational biology capabilities improving - partners may develop similar allosteric discovery platforms internally
Academic centers and biotech competitors adopting AI/ML for drug discovery at accelerating pace
Cash runway risk - estimated $600M cash against $200M annual burn implies need for financing by 2028-2029 absent partnership influx or revenue generation
Equity dilution risk - future raises at depressed valuations would significantly dilute existing shareholders; company has raised ~$800M cumulatively
Collaboration dependency - loss of Genentech partnership or failure to secure new deals would accelerate cash consumption
Minimal debt provides flexibility but also means no tax shield benefits and full reliance on equity markets
low - Biotech clinical development timelines and regulatory processes are largely insulated from GDP fluctuations. Patient enrollment in oncology trials continues regardless of economic conditions. However, severe recessions can impact: (1) ability to raise capital as risk appetite contracts, (2) partnership activity as pharma companies conserve cash, (3) acquisition multiples for M&A exits. The 159% six-month return suggests momentum driven by clinical catalysts rather than macro factors.
High sensitivity to interest rate environment through multiple channels: (1) Valuation multiples compress as risk-free rates rise - biotech DCF models heavily weight distant cash flows that get discounted more aggressively, (2) Cost of capital increases for future financing rounds, (3) Investor rotation from growth/speculative assets to fixed income when yields are attractive. The 2022-2023 biotech bear market coincided with Fed tightening. Current 19.14x current ratio provides cushion, but eventual need for capital raises makes rate environment critical.
Minimal direct credit exposure - company is not lending-dependent and maintains cash in liquid instruments. Indirect exposure through: (1) Pharma partner financial health affecting milestone payment reliability, (2) CRO and manufacturing vendor stability, (3) Ability to access credit markets if equity financing unavailable. Debt/equity of 0.05 indicates negligible leverage.
growth/speculative - Attracts biotech specialists, hedge funds with event-driven strategies around clinical catalysts, and growth investors willing to accept binary risk/reward. The 134% one-year return and high volatility profile appeal to momentum traders. Institutional ownership likely concentrated among healthcare-focused funds. Not suitable for income investors (no dividend) or conservative value investors (no earnings, high cash burn). Requires 3-5 year investment horizon to clinical inflection points.
high - Clinical-stage biotech with binary event risk exhibits 60-80% annualized volatility typical of the subsector. Single-day moves of 20-40% common around data readouts. The 159% six-month return followed by potential sharp reversals exemplifies volatility. Estimated beta of 1.5-2.0x versus broader market, higher versus biotech indices during risk-off periods.
